IP Library Granted Patent US 9,132,148
Granted Patent B2
US 9,132,148 · App. 13/848,249 · Granted Sep 15, 2015

Gene silencing by single-stranded polynucleotides

Inventor: Gretchen M. Unger (Chaska, MN)
Assignee: GeneSegues, Inc.
A61K31/7125C12N15/111C12N15/113C12N2310/11C12N2310/14C12N2310/315C12N2310/321C12N2310/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,148
App. No.
13/848,249
Granted
Sep 15, 2015
Kind
B2
Abstract

The present invention relates to compositions and methods for concurrently activating antisense and double-stranded RNase (dsRNase) mechanisms for inhibiting expression of a targeted gene, by delivering a single stranded bifunctional chimeric DNA/RNA oligonucleotide optimized for siRNA activity as well as antisense activity, into the nucleus of a target cell.

Claims (8)

1. A method for inhibiting expression of a target gene in a tumor cell, wherein the target gene is Casein Kinase 2, comprising: administering a formulation of single stranded polynucleotides to a mammal in an amount sufficient to inhibit expression of the target gene in the tumor cell, wherein said formulation is prepared according to a process comprising:

employing a suitable siRNA design algorithm to identify a candidate functional double stranded siRNA to a target RNA;

synthesizing a single stranded polynucleotide sequence comprising at least a portion of the guidestrand of the candidate functional double stranded siRNA, wherein a functional single stranded polynucleotide consisting of 15-25 linked nucleosides without a self-complementary sequence region is formed; wherein the functional single stranded polynucleotide sequence comprises a 3′ RNA portion and a 5′ DNA portion, wherein the functional single stranded polynucleotide comprises at least three consecutive ribonucleotides at the 3′ end, wherein the functional single stranded polynucleotide is at least 50% DNA, wherein each of the internucleoside linkages of the functional single stranded polynucleotide is a phosphodiester linkage; and

formulating a plurality of the functional single stranded polynucleotides, in the absence of a passenger strand, with a pharmaceutically acceptable non-viral carrier;

wherein the formulation is introduced into the tumor cell,

wherein the functional single stranded polynucleotides of the formulation are delivered to the perinuclear region or the nucleus of the tumor cell,

whereupon said functional single-stranded polynucleotides concurrently activate dsRNAse and RNAseH mechanisms of the cell, thereby inhibiting expression of the target gene in the tumor cell.

2. The method of claim 1 , wherein the functional single stranded polynucleotides do not comprise extrinsic 5′ phosphorylation.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 3, 2017
From: GENESEGUES, INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041231/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: UNGER, GRETCHEN M.
To: GENESEGUES, INC.
Reel/Frame 030675/0651 →
Continuity (3)
Continuation 12525652
Provisional Application 60898674 · Feb 1, 2007
Related Publication 20130267577A1 · Oct 10, 2013